Inhibition of HMG CoA Reductase and Lipid Peroxidation in The Rats Liver by Selected Zingiberaceae

Authors

  • Patonah Hasimun Bandung School of Pharmacy, STFB
  • Agus Sulaeman Bandung School of Pharmacy, STFB
  • Hendra Mahakam Putra Bandung School of Pharmacy, STFB
  • Heni Lindasari Bandung School of Pharmacy, STFB

DOI:

https://doi.org/10.12928/pharmaciana.v8i2.9430

Keywords:

hyperlipidemia, HMG-CoA reductase inhibitor, lipid peroxidation, zingiberaceae

Abstract

Cardiovascular disease is the leading cause of death worldwide. One of the major risk factors for cardiovascular disease is hyperlipidemia. This study aimed to determine the potential of Zingiberaceae (10 species) as inhibitor of HMG-CoA reductase enzyme activity and lipid peroxidation. This study was conducted by 2 methods including assay of HMG CoA reductase inhibition and lipid peroxidation test. The study was performed by in vitro method, using 20% rat liver homogenate. The inhibition of HMG CoA reductase enzyme was done by reacting liver homogenate, HMG CoA substrate, which added the Zingiberaceae extract compared with simvastatin as standard drug. The absorbance of the mixture was measured by a Microlab 300 spectrophotometer at a 340 nm wavelength. Lipid peroxidation assay was induced by the FeSO4.7H2O solution. The absorbance value measured using a spectrophotometer at a 532 nm wavelength. Lipid peroxidation inhibition was characterized by absorbance of the test extract, compared with the control group. The obtained data was calculated as percent of inhibition and was used to calculate IC50 extract test. The results showed that the 10 ethanolic extracts of Zingiberaceae rhizomes have activity as enzyme inhibitor HMG-CoA reductase with IC50 value range 65.8±4.1 – 203.3±15.2 ppm, and inhibition of lipid peroxidation with IC50 value range 13.5±5.0 – 219.6±4.3 ppm. This study can be concluded that the Zingiberaceae rhizomes have potential role as antihyperlipidemic agents through inhibition of HMG CoA reductase enzyme activity and preventing lipid peroxidation.

Author Biographies

Patonah Hasimun, Bandung School of Pharmacy, STFB

Pharmacology Research Group

Agus Sulaeman, Bandung School of Pharmacy, STFB

Pharmacology Research Group

Hendra Mahakam Putra, Bandung School of Pharmacy, STFB

Pharmacology Research Group

Heni Lindasari, Bandung School of Pharmacy, STFB

Pharmacology Research Group

References

Bhalavi, V., Deshmukh, P., Atram, M., Mahajan, B., 2015, Study of hypertension and hyperlipidemia in the adolescent of central India, International Journal Of Recent Trends In Science And Technology, 10(3): 495–498.

Blum, A., 2014, HMGâ€CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells—new mechanistic insights of atherosclerosis, Biofactors, 40(3): 295–302.

Felfoul, I., Borchani, M., Samet-Bali, O., Attia, H., Ayadi, M A., 2017, Effect of ginger (Zingiber officinalis) addition on fermented bovine milk: rheological properties, sensory attributes and antioxidant potential, Journal of New Sciences, 44: 2400–2409.

Gholampour, F., Ghiasabadi, F. B., Owji, Seyed M., Vatanparast, J., 2017, The protective effect of hydroalcoholic extract of Ginger (Zingiber officinale Rosc.) against iron-induced functional and histological damages in rat liver and kidney, Avicenna journal of phytomedicine, 7(6): 542.

Hasimun, P., Adnyana, I K., Valentina, R., Lisnasari, E., 2016, Potential alpha-glucosidase inhibitor from selected Zingiberaceae family, Asian Journal of Pharmaceutical and Clinical Research, 9: 164–167.

Kajal, A., Kishore, L., Kaur, N., Gollen, R., Singh, R., 2016, Therapeutic agents for the management of atherosclerosis from herbal sources, Beni-Suef University Journal of Basic and Applied Sciences, 5(2): 156–169.

Khandouzi, N., Shidfar, F., Rajab, A., Rahideh, T., Hosseini, P., Taheri, M. M., 2015, The effects of ginger on fasting blood sugar, hemoglobin A1c, apolipoprotein B, apolipoprotein AI and malondialdehyde in type 2 diabetic patients, Iranian journal of pharmaceutical research: IJPR, 14(1): 131.

Mendis, S., Puska, P., Norrving, B., 2011, Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization.

Moriel, P., Plavnik, Frida L., Zanella, M. T., Bertolami, M. C., Abdalla, DSP., 2000, Lipid peroxidation and antioxidants in hyperlipidemia and hypertension, Biological Research, 33(2): 105–112.

Qudoos, A., Nia, K., Hakro, S., Murad, S., 2016, Single Blind Placebo-Controlled Study On Comparision Of Effects Of Zingiber Officinale Before And After Treatment In Hyperlipidemia, Journal of Drug Delivery and Therapeutics, 6(3): 90–92.

Rader, D. J.., Hovingh, G. K., 2014, HDL and cardiovascular disease, The Lancet, 384(9943): 618–625.

Rouhi-Boroujeni, H., Rouhi-Boroujeni, H., Heidarian, E., Mohammadizadeh, F., Rafieian-Kopaei, M., 2015, Herbs with anti-lipid effects and their interactions with statins as a chemical anti-hyperlipidemia group drugs: A systematic review, ARYA atherosclerosis, 11(4): 244.

Selvam, R., Kurien, T. B., 1987, Induction of lipid peroxidation by oxalate in experimental rat urolithiasis’, Journal of Biosciences, 12(4): 367.

Shidfar, F., Rajab, A., Rahideh, T., Khandouzi, N., Hosseini, S., Shidfar, S., 2015, The effect of ginger (Zingiber officinale) on glycemic markers in patients with type 2 diabetes, Journal of Complementary and Integrative Medicine, 12(2): 165–170.

Srinivasan, K., 2017, Ginger rhizomes (Zingiber officinale): a spice with multiple health beneficial potentials, Pharma Nutrition, 5(1): 18–28.

Tohma, ., Gülçin, İ., Bursal, E., Gören, A. C., Alwasel, S. H., Köksal, E., 2017, Antioxidant activity and phenolic compounds of ginger (Zingiber officinale Rosc.) determined by HPLC-MS/MS, Journal of Food Measurement and Characterization, 11(2): 556–566.

Tripathi, P., Singh, A., 2015, Indigenous Asian Plants against Cancer: A Comprehensive Review, International Journal of Plant Research, 5(4): 80–86.

Trpkovic, A., Resanovic, I., Stanimirovic, J., Radak, D., Mousa, S.A., Cenic-Milosevic, D., Jevremovic, D., Isenovic, E. R., 2015, Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases, Critical reviews in clinical laboratory sciences, 52(2): 70–85.

Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., DiPiro, C. V., 2014, Pharmacotherapy Handbook, 9/E. McGraw Hill Professional.

Würtz, P., Wang, Q., Soininen, P., Kangas, A. J., Fatemifar, G., Tynkkynen, T., Tiainen, M., Perola, M., Tillin, T., Hughes, A. D., 2016, Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase, Journal of the American College of Cardiology, 67(10): 1200–1210.

Downloads

Published

2018-12-06

Issue

Section

Pharmacology